Human epidermal growth factor receptor 2 - positive
Showing 1 - 25 of >10,000
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab
Recruiting
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
- Sacituzumab Govitecan-hziy
- +3 more
-
Marietta, Georgia
- +1 more
Apr 21, 2023
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)
Recruiting
- Metastatic Breast Cancer
- +2 more
-
Ocala, FloridaOcala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)
Not yet recruiting
- Breast Cancer
- Breast Cancer, Early-Onset
- (no location specified)
Jan 18, 2023
Advanced or Metastatic Breast Cancer Trial in Nashville (AND019 PO QD)
Not yet recruiting
- Advanced or Metastatic Breast Cancer
- AND019 PO QD
-
Nashville, TennesseeSarah Cannon Research Institute
Jul 19, 2022
HER2-positive Breast Cancer Trial in Tampa (biological, drug, procedure)
Recruiting
- HER2-positive Breast Cancer
- HER-2 pulsed DC1
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 6, 2022
Older Women With ER Positive, HER2 Negative Early Breast Cancer
Enrolling by invitation
- Breast Cancer Female
- Translational study
-
Sutton, United KingdomThe Royal Marsden NHS Foundation Trust
Feb 8, 2023
Adenocarcinoma, Gastric, Tumor, Breast Trial in Taipei (DS-8201a)
Completed
- Adenocarcinoma, Gastric
- Neoplasm, Breast
-
Taipei, Taiwan
- +1 more
Nov 2, 2022
Breast Cancer Trial in Shanghai (Pertuzumab)
Not yet recruiting
- Breast Cancer
-
Shanghai, Shanghai, ChinaShanghai Jiaotong University School of Medicine affiliated Ruiji
Jun 4, 2023
Breast Cancer Trial in New York (core needle biopsy, blood draw)
Recruiting
- Breast Cancer
- core needle biopsy
- blood draw
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Nov 9, 2023
Breast Cancer Trial in Orange City (ARV-471 (PF-07850327), Palbociclib, Letrozole)
Recruiting
- Breast Cancer
- ARV-471 (PF-07850327)
- +2 more
-
Orange City, FloridaMid Florida Hematology and Oncology Center
Jun 8, 2023
Breast Cancer Trial in Chuo-Ku, Kashiwa-Shi, Nagoya-Shi (Amcenestrant (SAR439859))
Active, not recruiting
- Breast Cancer
- Amcenestrant (SAR439859)
-
Chuo-Ku, Japan
- +2 more
Nov 16, 2022
Breast Cancer Stage II Trial in Xi'an (Anlotinib)
Recruiting
- Breast Cancer Stage II
-
Xi'an, Shannxi Province, ChinaXijing Hospital Affiliated to Air Force Military Medical Univers
Sep 25, 2022
Metastatic Breast Cancer Trial in Dallas (DB-1303, Capecitabine, Paclitaxel)
Not yet recruiting
- Metastatic Breast Cancer
- DB-1303
- +3 more
-
Dallas, TexasTexas Oncology - Baylor Charles A. Sammons Cancer Center
Aug 25, 2023
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023